Working To Enhance The Quality Of Life
In Baltimore And In Maryland.

You are here

Current Investments

The Abell Foundation’s direct investments are return-driven with a triple bottom-line focus consistent with its mission priorities.


Please click on a company name to see details about that investment.


PAICE is a company that has been at the forefront of the hybrid-vehicle industry for nearly 20 years, developing technology capable of significantly improving driving performance, maximizing fuel efficiency, reducing harmful emissions, and lowering costs. Its inventions have been recognized with 13 U.S. patents and numerous foreign patents, including four of the world’s 10 most dominant hybrid vehicle patents according to a study by Griffith Hack. PAICE has established long-term licensing agreements with Toyota, Ford, and Hyndai, three of the world’s largest automakers for its hybrid technology. For more information, visit

ThermoChem Recovery International, Inc. (TRI)

TRI has developed a set of proprietary gasification technologies that provide the foundation for state-of-the-art conversion of biomass into green fuels, chemicals and renewable energy. TRI‘s steam-reforming gasification process converts cellulosic feedstocks (including post-sorted Municipal Solid Waste (MSW), bark, forest residuals, agricultural waste, energy crops and low rank coals) into a synthesis gas (“syngas”) which can be converted into biofuels and biochemical, or used to replace fossil fuels for power generation.  TRI’s proprietary process uniquely removes contaminants in solid form, making it a particularly good technology for conversion of MSW, with far superior emissions as compared to existing waste-to-energy plants.   TRI licenses its proprietary gasification technology—including biomass feeders, gasification and gas clean-up—and provides specialized equipment and engineering services to companies seeking to integrate TRI's process into their operations. TRI’s proven technology has been demonstrated at commercial scale at the Norampac Trenton mill in Ontario, Canada. For more information, visit

OTEC International LLC (OTI)

Ocean Thermal Energy Conversion (OTEC) is an important renewable energy technology that harnesses the vast solar energy stored in the upper layers of the tropical oceans to produce electricity. In contrast to conventional solar and wind projects, OTEC can generate power 24 hours a day, 365 days a year. OTI has developed proprietary designs, including 18 issued or U.S. patents pending, to efficiently convert this thermal energy into a commercially viable alternative to conventional fossil fuel power plants. Leveraging more than 40 years of OTEC R&D, OTI has received the first-ever approval in principal for its floating base load power plants and is in the forefront of commercial development with contracts in Hawaii and Grand Cayman. See for additional information.

CeraTech, Inc.

Ceratech, Inc. has pioneered and commercialized a product line of high performing green cement, which is comprised of more than 90 percent recycled waste streams. Founded in 2001 and based in Baltimore, MD, CeraTech’s concrete repair and rehabilitation products are currently in use by the U.S. military in combat operations around the world as well as domestic transportation departments, municipalities, aviation and port authorities, and commercial construction companies. CeraTech uses fly ash, a waste product of coal-fired power plants, to produce its high- performance cement. In 2011, CeraTech received strategic equity investments from three publicly traded companies to accelerate market penetration of its proprietary products, starting in the U.S. For more information, visit

BioMarker Strategies 

BioMarker Strategies is developing a novel automated tumor biopsy processing and testing system, called SnapPath™, designed to quickly test and analyze a patient’s live solid tumor sample at the point of biopsy.  These functional, pathway-based, ex vivo biomarker tests will help guide an oncologist’s use of targeted cancer therapeutics. The SnapPath™ technology is also designed to reduce patient waiting times for molecular diagnostic test results from several weeks to several hours. The company is one of the first commercial tenants at the Johns Hopkins Science + Technology Park in East Baltimore developed by the Forest City-New East Baltimore Partnership. For more information, visit

Pixelligent Technologies 

Pixelligent Technologies produces proprietary groundbreaking nanocrystal additives that can be deployed in a wide variety of commercial applications including electronics, metal coatings, lubricants and the solar market. The company is the first in the field to demonstrate the ability to scale up the nanocrystal additive materials for commercial deployment. In its initial applications to the electronic and semiconductor markets, the nanocrystal additives dramatically improve the etch resistance—a critical step used to manufacture computer chips and enhance the efficiency and performance of digital displays and high brightness LEDs. Pixelligent is headquartered in Baltimore, MD. Visit for additional information.


eNeura Therapeutics, a privately held medical technology company, has developed a portable, non-invasive Transcranial Magnetic Stimulation (TMS) device for treatment of migraine headaches. Many patients are unable to utilize traditional methods of treatment because of medications currently offered. With the use of magnetic pulsing, TMS allows migraine patients to administer treatment as needed. This technology has been approved and licensed for sale in Europe with expected FDA approval in the U.S. in 2014. For more information, visit

Network for Good

Network for Good is a fundraising technology platform that supports charitable giving through customized web pages and mobile applications. Network for Good combines storytelling and social marketing to engage and inspire tech savvy adults to areas of passion and commitment. The company uses a social media model for multiple non-profit organizations to efficiently fundraise small donations.  Educational institutions and large nonprofits can private label their fundraising efforts and manage multiple donor channels leveraging the innovative platform. For more information, visit

Common Curriculum

Common Curriculum is an educational tool developed by two Teach For America graduates to innovate lesson planning, sharing and scheduling. This application provides an efficient tool for teachers and school districts to meet Common Core standards. Visit for more information.


Noxilizer is a biotechnology company that has developed a faster, less expensive, environmentally friendly, room temperature NO2-based sterilizer for the medical industry. It is also developing a system especially for sensitive, high-tech equipment used in minimally invasive surgical procedures. For more information, visit


Gliknik is a bio-pharmaceuticals company that has developed new therapies for patients with cancer and autoimmune/inflammatory diseases. It also has commercial rights to two cancer immunomodulator drugs that are in multiple-dose clinical trials in patients with advanced head and neck cancer and in patients with advanced multiple myeloma.


GrayBug is a biotech company with a proprietary drug for age-related macular degeneration (AMD) and other diseases that involve unwanted growth of new blood vessels. The company has two proprietary platform drug delivery technologies for ophthalmic pharmaceutical indications, and proof-of-concept (POC) data in multiple animal models for its lead product in AMD, diabetic retinopathy (DR), corneal graft rejection, and four different drugs for glaucoma. GrayBug has obtained an exclusive worldwide license to certain patents from the Johns Hopkins University School of Medicine. For more information, visit

Sonify Biosciences

Sonify Biosciences exists to explore the potential of low-intensity ultrasound as a novel melanoma treatment.  

Propel Baltimore Fund

The Propel Baltimore Fund (PBF) was created by The Abell Foundation, in conjunction with the Maryland Technology Development Corporation (TEDCO).  The PBF, which is open to other institutional investors, was created to support the establishment and development of promising businesses in Baltimore and to help ensure that innovators recognize Baltimore as an attractive location to start, build, and sustain their companies.  The Fund will provide up to a $250,000 investment in early-stage technology companies. See for more information.

Harpoon Medical, Inc.

Harpoon Medical, Inc. is a development stage medical device company commercializing a minimally invasive, image guided surgical tool for beating heart mitral valve repair. The technology was developed in the division of Cardiac Surgery at The University of Maryland School of Medicine. With the Harpoon device, surgeons can access and repair the mitral valve in a beating heart via a small incision between the ribs without the need for cardiac arrest or cardiopulmonary bypass. When introduced to the market, the Harpoon device should transform the traditional open heart mitral valve surgical procedure from a complex 3-6 hour operation to a 60-minute procedure and reduce the recovery period from weeks to days. See


Vaccinogen is a biotechnology company with more than three decades of research into combating cancer by using the body’s own immune system. It is the producer of OncoVAX®, an immunotherapy for Stage II colon cancer that involves using the patient’s own cancer cells to prevent the disease from recurring. The vaccine has demonstrated its effectiveness and safety in early trials. The company has established the manufacturing capability to produce OncoVAX® for a Phase IIIb trial. See

Breethe, Inc.

Breethe, Inc. is committed to delivering new product options for patients suffering respiratory failure, cardiac arrest, and cardiopulmonary collapse.  The initial focus is to bring the world’s first wearable out-of-hospital artificial lung to market.  Based on unique technology developed at University of Maryland, Baltimore and supported by a $5 million NIH award, the company intends to move the use of the artificial lung into humans within the next 2-3 years. Breethe received an allocation of Maryland Biotechnology Tax Credits to support its fundraising efforts in 2014.

Vasoptic Medical

In the United States, nearly 29 million people, or 9% of the population, have diabetes, with an additional 8 million estimated to be undiagnosed.  Globally, more than 371 million people currently suffer from diabetes, a population that is expected to grow to well over 550 million by 2030.  Approximately 1 in 3 diabetics currently suffer from DR, a medical condition that can results in loss of vision from prolonged mismanagement of diabetes. Unfortunately, as few as 50% of diabetics receive the recommended annual eye exam, while up to 36% of diabetics have never had an exam.

Vasoptic Medical has developed a low-cost, easy-to-use, mobile detection device that rapidly captures information at an early stage and can be used in primary care offices and community clinic worldwide, allowing optical health information to be integrated into diabetes management systems. See

Perceptive Navigation

Perceptive Navigation is a Baltimore-based medical device company that created an image-guided probe to be used in the areas of interventional radiology, cardiology,  oncology, pulmonology, and urology making procedures safer with greater accuracy. This technology provides ultrasound guidance with needle access reducing multiple procedures to a one-step process. See


Sonavex’s creation of the EchoSure system is a medical technology that rapidly detects and removes blood clots arising from surgical procedures. Through the use of advance tracking algorithms, users are guided to the potential clot where blood flow data is extracted. See

Personal Genome Diagnostics

Personal Genome Diagnostics founded by researchers from Johns Hopkins University provides a host of cancer genome analyses services to identify changes in cancer related genes. Some of these changes including genome sequence, changes in the copy number of specific genes, and genome joining or sequence rearrangements.  See


CoolTech has developed a portable device for EMTs and first responders to start the cooling process immediately for stroke and heart attack patients. Through the use of a portable, transnasal cooling process, beneficial patient cooling protocols are accelerated by eliminating the wait time to receive in-hospital specialty care.


Contact Us

It is difficult to fully understand an investment opportunity based on a phone call. If you have a funding proposal for a company located or willing to locate in Baltimore City, please send us an executive summary and an email address where you can be reached.

Please send executive summaries either via email to, or by mail to:

Robert C. Embry, Jr.
The Abell Foundation
Suite 2300
111 S. Calvert Street
Baltimore, MD 21202-6174

Phone: (410) 547-1300
Fax: (410) 539-6579